BERLIN and SEATTLE, June 9, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer based on DNA methylation, today announced that it successfully completed a clinical study in its lung cancer program. The study was run in close collaboration with Prof. Dr. Christian Witt and Dr. Bernd Schmidt at the Charite -- Universitatsmedizin Berlin, Germany.
